Financial giants have made a conspicuous bearish move on Johnson & Johnson. Our analysis of options history for Johnson & Johnson JNJ revealed 10 unusual trades. Delving into the details, we found 20% ...

The steady increase in stocks shifting into long-term bear market trends has implications for the broader market as we head into 2025. The negative momentum that is building is likely to create a ...

ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S.

Johnson & Johnson (JNJ) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in ...

With its stock down 12% over the past three months, it is easy to disregard Johnson & Johnson (NYSE:JNJ). However, stock ...

Royal Bank of Canada recently reported solid results that showed year-over-year growth in most areas. Find out why RY stock ...

In a report released on December 10, Alistair Campbell from RBC Capital maintained a Buy rating on Genmab A/S (0MGB – Research Report), with a ...

BofA Securities has recently resumed Johnson & Johnson (JNJ) stock to Neutral rating, as announced on December 10, 2024, according to Finviz. Earlier, on November 15, 2024, Wolfe Research had ...

Shares of Johnson & Johnson JNJ slid 0.27% to $146.24 Thursday, on what proved to be an all-around rough trading session for ...